IL273485A - Enhanced delivery epinephrine and prodrug compositions - Google Patents
Enhanced delivery epinephrine and prodrug compositionsInfo
- Publication number
- IL273485A IL273485A IL273485A IL27348520A IL273485A IL 273485 A IL273485 A IL 273485A IL 273485 A IL273485 A IL 273485A IL 27348520 A IL27348520 A IL 27348520A IL 273485 A IL273485 A IL 273485A
- Authority
- IL
- Israel
- Prior art keywords
- epinephrine
- enhanced delivery
- prodrug compositions
- prodrug
- compositions
- Prior art date
Links
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 title 1
- 229930182837 (R)-adrenaline Natural products 0.000 title 1
- 229960005139 epinephrine Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/717,859 US20180125977A1 (en) | 2016-05-05 | 2017-09-27 | Enhanced delivery epinephrine compositions |
US15/791,249 US20180104195A1 (en) | 2016-05-05 | 2017-10-23 | Enhanced delivery epinephrine compositions |
PCT/US2018/053042 WO2019067670A1 (en) | 2017-09-27 | 2018-09-27 | Enhanced delivery epinephrine and prodrug compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
IL273485A true IL273485A (en) | 2020-05-31 |
IL273485B1 IL273485B1 (en) | 2024-07-01 |
Family
ID=63858169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL273485A IL273485B1 (en) | 2017-09-27 | 2018-09-27 | Enhanced delivery epinephrine and prodrug compositions |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP3687510A1 (en) |
JP (2) | JP2020535162A (en) |
KR (1) | KR20200060748A (en) |
CN (1) | CN111465391A (en) |
BR (1) | BR112020005948A2 (en) |
CA (1) | CA3076816A1 (en) |
IL (1) | IL273485B1 (en) |
WO (1) | WO2019067670A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109310646A (en) | 2016-05-05 | 2019-02-05 | 阿奎斯蒂弗医疗股份有限公司 | Enhance the adrenaline composition of delivering |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
AU2020373100A1 (en) | 2019-11-01 | 2022-05-19 | Aquestive Therapeutics, Inc. | Prodrug compositions and methods of treatment |
US11571468B2 (en) * | 2021-02-01 | 2023-02-07 | Matthias W. Rath | Micronutrient combination to reduce blood pressure |
US20240016734A1 (en) * | 2022-06-14 | 2024-01-18 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
EP4302751A1 (en) * | 2022-07-07 | 2024-01-10 | LTS Lohmann Therapie-Systeme AG | Oral thin films with low water activity |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7666337B2 (en) | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
US7425292B2 (en) | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US20030143195A1 (en) * | 2002-01-30 | 2003-07-31 | Pinsker Judy Senior | Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery |
US20040096569A1 (en) * | 2002-11-15 | 2004-05-20 | Barkalow David G. | Edible film products and methods of making same |
US20050266085A1 (en) * | 2004-05-28 | 2005-12-01 | Warner Kevin S | Gelled emulsion and microemulsion formulations for dermal drug delivery |
US20070202163A1 (en) * | 2005-09-09 | 2007-08-30 | Mutasem Rawas-Qalaji | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
IL175338A0 (en) * | 2006-05-01 | 2006-09-05 | Biota Ltd | Orally administrable films and preparation thereof |
US20070293582A1 (en) * | 2006-06-05 | 2007-12-20 | Malcolm Hill | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
WO2007143674A2 (en) * | 2006-06-05 | 2007-12-13 | Verus Pharmaceuticals, Inc. | Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies |
PE20091084A1 (en) * | 2007-12-07 | 2009-07-23 | Schering Plough Healthcare | PHARMACEUTICAL FORMULATIONS OF PHENYLPHRINE AND COMPOSITIONS FOR TRANSMUCOSAL ABSORPTION |
CA2756879A1 (en) * | 2009-04-23 | 2010-10-28 | Londonpharma Ltd. | Sublingual pharmaceutical composition comprising a neutral oil |
MX2012011355A (en) * | 2010-03-30 | 2012-11-30 | Phosphagenics Ltd | Transdermal delivery patch. |
EP2770949A4 (en) * | 2011-10-28 | 2015-07-08 | Sung-Yun Kwon | Dissolving solid solution perforator patch for migraine treatment |
MY191875A (en) * | 2012-10-11 | 2022-07-18 | Ix Biopharma Ltd | Solid dosage form |
US20160051494A1 (en) * | 2014-08-21 | 2016-02-25 | Mylan, Inc. | Multi-dose medication kit for treating anaphylaxis |
CN109310646A (en) * | 2016-05-05 | 2019-02-05 | 阿奎斯蒂弗医疗股份有限公司 | Enhance the adrenaline composition of delivering |
EP3452024A1 (en) * | 2016-05-05 | 2019-03-13 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
EP3687508A1 (en) * | 2017-09-26 | 2020-08-05 | Aquestive Therapeutics, Inc. | Delivery pharmaceutical compositions including permeation enhancers |
-
2018
- 2018-09-27 KR KR1020207012106A patent/KR20200060748A/en not_active Application Discontinuation
- 2018-09-27 CA CA3076816A patent/CA3076816A1/en active Pending
- 2018-09-27 JP JP2020517419A patent/JP2020535162A/en active Pending
- 2018-09-27 CN CN201880063175.3A patent/CN111465391A/en active Pending
- 2018-09-27 EP EP18786593.6A patent/EP3687510A1/en active Pending
- 2018-09-27 WO PCT/US2018/053042 patent/WO2019067670A1/en active Application Filing
- 2018-09-27 BR BR112020005948-0A patent/BR112020005948A2/en unknown
- 2018-09-27 IL IL273485A patent/IL273485B1/en unknown
-
2023
- 2023-08-03 JP JP2023126682A patent/JP2023159150A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL273485B1 (en) | 2024-07-01 |
KR20200060748A (en) | 2020-06-01 |
CN111465391A (en) | 2020-07-28 |
EP3687510A1 (en) | 2020-08-05 |
BR112020005948A2 (en) | 2020-12-01 |
CA3076816A1 (en) | 2019-04-04 |
JP2023159150A (en) | 2023-10-31 |
JP2020535162A (en) | 2020-12-03 |
WO2019067670A1 (en) | 2019-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273823A (en) | Methods and compositions for topical delivery | |
HK1258900A1 (en) | Delivery methods and compositions | |
IL262750B (en) | Enhanced delivery epinephrine compositions | |
IL272232A (en) | Glp-1 compositions and uses thereof | |
HUE050894T2 (en) | Compositions comprising a combination of ipilimumab and nivolumab | |
IL271275A (en) | Compositions comprising curons and uses thereof | |
IL273485A (en) | Enhanced delivery epinephrine and prodrug compositions | |
ZA202001044B (en) | Drug delivery composition | |
IL271759B1 (en) | Pharmaceutical compositions comprising entrectinib | |
SG10202112759SA (en) | Antimalarial compositions and uses thereof | |
HK1245113A1 (en) | Pharmaceutical compositions and use thereof | |
IL279877A (en) | Ivosidenib forms and pharmaceutical compositions | |
IL277441A (en) | Lfa3 variants and compositions and uses thereof | |
ZA201903341B (en) | Pharmaceutical compositions and uses thereof | |
GB201812952D0 (en) | Compositions and uses thereof | |
GB201702546D0 (en) | Oral delivery compositions | |
GB201713920D0 (en) | Pharmaceutical compositions and uses thereof | |
GB201711779D0 (en) | Delivery | |
GB201711222D0 (en) | Delivery formulation | |
IL252660B (en) | Inverse-freezing compositions and use thereof | |
GB201707035D0 (en) | Drug delivery composition | |
GB201706968D0 (en) | Drug delivery composition | |
GB201604810D0 (en) | Pharmaceutical compositions and uses | |
GB201602406D0 (en) | Compositions and uses thereof | |
GB201602398D0 (en) | Compositions and uses thereof |